Literature DB >> 20185008

Relation of race (Asian, African-American, European-American, and Hispanic) to activated clotting time after weight-adjusted bolus of heparin during percutaneous coronary intervention.

Yuichi J Shimada1, Navin C Nakra, John T Fox, Yumiko Kanei.   

Abstract

A weight-adjusted bolus of heparin (70 to 100 IU/kg) is recommended to achieve adequate anticoagulation during percutaneous coronary intervention (PCI). Proper dosing is mandatory to avoid bleeding and thrombotic complications. We investigated whether sensitivity to heparin is affected by difference in race. We performed a retrospective study with 874 consecutive PCI cases in our catheterization laboratory. The amount of initial heparin bolus (international units) per weight and subsequent activated clotting time (ACT; seconds) were obtained. Patients were divided into 4 categories based on race: Asian, African-American, European-American, and Hispanic. Multiple regression analysis was performed to validate the variables that determine the ACT. After adjusting for these variables, analysis of variance revealed the presence of a significant racial difference in ACT (p = 0.002). Successively, Student-Newman-Keuls test and Bonferroni t test revealed that Asian patients have higher ACT levels compared to other racial groups (p <0.03 for Asian vs others, p >0.26 between non-Asian groups). There was a positive relation between ACT and Asian race (p = 0.0004). Further analyses showed that Asians require 10 IU/kg less heparin per weight than other racial groups to achieve the same goal of ACT. In conclusion, decreased heparin dosing should be considered for Asian patients undergoing PCI. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20185008     DOI: 10.1016/j.amjcard.2009.10.043

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

Review 1.  Point-of-care testing for anticoagulation monitoring in neuroendovascular procedures.

Authors:  H M Hussein; A L Georgiadis; A I Qureshi
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-15       Impact factor: 3.825

Review 2.  Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies.

Authors:  Ziad Sergie; Thierry Lefèvre; Eric Van Belle; Socrates Kakoulides; Usman Baber; Efthymios N Deliargyris; Roxana Mehran; Eberhard Grube; Jochen Reinöhl; George D Dangas
Journal:  J Thromb Thrombolysis       Date:  2013-05       Impact factor: 2.300

Review 3.  Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Yanzhi Song; Xiaodong Li; Settipalli Pavithra; Dong Li
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

4.  Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects.

Authors:  Yimin Cui; Yan Song; Jessie Wang; Zhigang Yu; Alan Schuster; Yu Chen Barrett; Charles Frost
Journal:  Clin Pharmacol       Date:  2013-12-06

5.  The technical features of the diagnosis or treatment of coronary artery disease through the distal radial artery approach at the anatomical snuffbox compared with the conventional radial artery approach.

Authors:  Yingkai Xu; Hongzhen Niu; Yi Yu; Lixia Yang; Haiyang Wang; Biyang Zhang; Qi Zhao; Qiang Yong; Yujie Zhou
Journal:  J Cardiothorac Surg       Date:  2022-09-07       Impact factor: 1.522

6.  Antifactor Xa levels in critically ill Korean patients receiving enoxaparin for thromboprophylaxis: a prospective observational study.

Authors:  So Yeon Lim; Kyeongman Jeon; Hee-Jin Kim; Seon Mi Kim; Junwhi Song; Jung Min Ha; Sang-Won Um; Won-Jung Koh; Man Pyo Chung; Hojoong Kim; O Jung Kwon; Gee Young Suh
Journal:  J Korean Med Sci       Date:  2013-03-04       Impact factor: 2.153

7.  Activated clotting time level with weight based heparin dosing during percutaneous coronary intervention and its determinant factors.

Authors:  Majid Soleimannejad; Naser Aslanabadi; Bahram Sohrabi; Morteza Shamshirgaran; Ahmad Separham; Babak Kazemi; Ebrahim Khayati Shal; Reza Madadi; Hamidreza Shirzadi; Hoda Azizi; Samad Ghaffari
Journal:  J Cardiovasc Thorac Res       Date:  2014-06-30

8.  Impact of sheath size and hemostasis time on radial artery patency after transradial coronary angiography and intervention in Japanese and non-Japanese patients: A substudy from RAP and BEAT (Radial Artery Patency and Bleeding, Efficacy, Adverse evenT) randomized multicenter trial.

Authors:  Adel Aminian; Shigeru Saito; Akihiko Takahashi; Ivo Bernat; Robert Lee Jobe; Takashi Kajiya; Ian C Gilchrist; Yves Louvard; Ferdinand Kiemeneij; Niels van Royen; Maarten van Leeuwen; Seiji Yamazaki; Takashi Matsukage; Juan F Iglesias; Sunil V Rao
Journal:  Catheter Cardiovasc Interv       Date:  2018-02-16       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.